Cargando…
2138. In Vitro Susceptibility of Recent Clinical Isolates of P. aeruginosa and Enterobacterales to Imipenem or Meropenem Alone or in Combination with Sulbactam-Durlobactam
BACKGROUND: Sulbactam-durlobactam (SUL-DUR) is a targeted β-lactam/β-lactamase inhibitor combination in development for the treatment of infections caused by Acinetobacter spp., including multidrug resistant strains. ATTACK was a global, active-controlled Phase 3 trial conducted to evaluate the effi...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677553/ http://dx.doi.org/10.1093/ofid/ofad500.1761 |